In this cohort study with 13 799 participants, initiation of SGLT2 inhibitors was associated with a 19% decrease in incident anemia risk compared with initiation of glucagon-like peptide-1 receptor agonists. The gene discussed is SLC5A2; the disease is anemia (phenotype).